Dr. Wesley M. Jose

Clinical Associate Professor

MBBS, MD (Internal Medicine), DNB (Medical Oncology), MNAMS, FIACM, PGDIM

Speciality: Heart Diseases, Medical Oncology, Amrita Cardio Oncology Clinic

Book an Appointment

Amrita Hospital Kochi

Overview

Investigator

Area of Interest

Achievements

Additional Training

Publications

Book Chapters

Conference Proceedings

Conference

Dr. Wesley M. Jose joined Amrita Institute of Medical Sciences in April 2008. Having over 20 years of clinical experience, he currently serves as Associate Professor at the Department of Medical Oncology and Hematology at Amrita.

Dr. Wesley did his undergraduate and postgraduate training from Christian Medical College and Hospital, Ludhiana, Punjab. Before joining Amrita in April 2008, he worked as Assistant Professor at the Department of Medicine at the Christian Medical College and Hospital, Ludhiana. He has presented scientific papers and continues to be an invited faculty / speaker for various scientific conferences.
He is experienced with conduct of clinical trials. He is the Principal Investigator for the following trials.

CTRI/2018/12/016813 – A Multicenter Registry Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice. CANSCRIPTTM REGISTRY OF CLINICAL UTILIZATION AND OUTCOME IN CANCER TREATMENTS (CAN-PREDICT)
SB3-G31-BC – A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin® in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting. (Sponsor: Samsung)
CBT124/CT/002 – A Randomized, Double-blind, Multicentric,Parallel-group Study Comparing Efficacy, Safety and Immunogenicity of CBT124, a Candidate Biosimilar Bevacizumab in Combination with Carboplatin and Paclitaxel with EU-sourced Avastin® in Combination with Carboplatin and Paclitaxel in First-line Treatment for Subjects with Stage IV (Unresectable Recurrent Disease or Metastatic) Non-squamous Non-Small Cell Lung Cancer (NSCLC). (Sponsor: CIPLA Biotec)
Lenalidomide and Short Course Dexamethasone In Newly Detected Multiple Myeloma – A Single Center Phase 2 Study (Sponsor: NATCO Laboratories)

RI-02-003
Reditux™ Registry to Compare Effectiveness, Safety, and Resource Utilization of Reditux™ vs. the Reference Medicinal Product to Treat Diffuse Large B-Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukaemia (CLL) in Routine Clinical Practice
LRP/LNP3794/2016/006
A Phase II/III Pivotal, Open-label, Randomized, 3 Arm Study to Assess the Efficacy of Lupin’s Molecule Monotherapy or in Combination with Docetaxel, Compared with Docetaxel Alone, in Patients with RAS Mutation Positive Locally Advanced and Metastatic Non-Small Cell Lung Cancer as Second Line Therapy
CLDK378A2301
A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer
Protocol No. 476-13
A Prospective, Comparative, Open Label, Randomized, Multicentric, Phase III study to compare the safety and efficacy of Bevacizumab of Intas Pharmaceuticals Limited against Avastin™ in Patients with Unresectable or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Protocol No. - CDP/03/07
"A randomized, multi-center, open label study to evaluate the efficacy and safety of Peg G-CSF as compared to Grafeel® in the prophylaxis of severe neutropenia in cancer patients receiving cytotoxic chemotherapy". (Sponsor: Dr. Reddy's Laboratories).
Protocol No. - MK-0683-088
"An international, Multi-center, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma". (Sponsor: Merck & Co Inc.)
Protocol No. - MORAb-003-004
"A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety Weekly Farletuzmab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum sensitive Ovarian Cancer in First Relapse" (Sponsor: Morphotek Inc.).
Protocol No: EGF 110656
"A Phase III Study of ERBB2 Positive Advanced or Metastatic Gastric or Esophageal or Gastro esophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib” (Sponsor:GlaxoSmithKline)
Protocol RI-01-002
“A Randomised, Multi-centre, Double-blind, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Two Anti-CD20 Monoclonal Antibodies in Combination with CHOP in Patients with CD20-Positive Diffuse Large B-cell Lymphoma”

Breast Cancer, Colorectal Cancers, Brain Tumors, Multiple Myeloma, Lymphoma and Pediatric Malignancies.

Felloeship

Indian Academy of Clinical Medicine (IACM)

Memberships

American Society of Clinical Oncology (ASCO)
European Society of Medical Oncology (ESMO)
Indian Academy of Cancer Research (IACR)
European Association for Cancer Research (EACR)
Indian Society of Medical and Pediatric Oncology (ISMPO)
Cooperative Trials Group for Neuro-Oncology (COGNO)
Indian Society of Neuro-Oncology (ISNO)
International CML foundation (iCMLf)
National Academy of Medical Sciences (NAMS)
Association of Physicians of India (API)
Indian Academy of Clinical Medicine (IACM)

Equator Network – CONSORT 2010 reporting guidelines - Oxford, UK, 2010.
Randomized Controlled Trials – Oxford, UK, 2010
Statistics for Health Research – Oxford, UK, 2010

Priyanka S, Jose W. Prolonged remission and good quality of life with maintenance chemotherapy in recurrent Ewing’s sarcoma. Journal of Clinical and Diagnostic Research 2018; 12 (3): XD01 - XD03.
Jose W, Pavithran K, Ganesan TS. Short course Lenalidomide plus Low Dose Dexamethasone in Treatment of Newly Diagnosed Multiple Myeloma – A Single Center Pragmatic study. Current Oncology 2017; 24 (5): 361-367. [DOI: https://doi.org/10.3747/co.24.3574] [PMID: 29089806]
James E, Drisya PM, Jose W. Olanzapine combined with standard antiemetic regimens for prevention of chemotherapy therapy-induced nausea and vomiting: a single-center experience from south India. Asian Journal of Pharmaceutical and Clinical Research 2017; 10 (11): 247-251.
Abdul MK, Palaniappan M, Kumar K, Jose W, Pavithran K, Ganesan TS. Capox As First Line Chemotherapy In Recurrent And Previously Untreated Metastatic Colorectal Cancer – An Experience From South India. Int J Recent Sci Res. 2016; 7(10): 14099-14102
Antony R, Lakshmi S, Sivadas A, Jose W, Sidharthan N, Pavithran K. Efficacy of fixed low dose rasburicase in the prevention and treatment of tumor lysis syndrome. Journal of Pharmaceutical Research 2015;14: 46.
Prameela CG, Rahul R, Zaheeruddin PM, Jose WM, Sheejamol VS, Dinesh M. Hyponatremia: Is there an association with disease profile in head and neck malignancies? Audit from a tertiary cancer care centre. JIPMER Journal of Cancer 2015; 5 (1): 14-25.
Philip, K. Pavithran, M. Jose, Jose W, P. Renjini, D.K. Vijaykumar, M. Dinesh, J. Annie, N. Seethalakshmi, N. Smitha. Neutrophil to lymphocyte ratio predicts lymph node metastasis in triple negative breast cancer. The Breast, 2015; 24 (Supplement 1), S110 (P245) [DOI: http://dx.doi.org/10.1016/S0960-9776(15)70277-8]
Muthu P, Unnikrishnan A, Jose WM, Keechilat P. A case of biphasic pulmonary blastoma showing good response to preoperative chemotherapy. Indian J Cancer 2014; 51:510-1. [PMID: 26842180]
Jose W, Boyella PK, Nair IR, Eapen M, Pavithran K. Revisiting: Cutaneous metastasis from Carcinoma Gall bladder. Ind J of Derm, Ven, and Lep 2014; 80(1): 82-85. [PMID: 24448139]
Jose W, Pavithran K. Neoadjuvant treatment for carcinoma bladder. Amrita Journal of Medicine 2013; 9(1): 22-25
Mehta AA, Jose W, Pavithran K, Ganesan TS. The Role Gefitinib in Patients with Non Small Cell Lung Cancer in India. Indian J Palliat Care 2013; 19 (1): 48-53. [PMID: 23766595]
Anupama R, Sarah Thomas B, Jose W, Pavithran K, Vijaykumar DK. Malignancies during Pregnancy – A Case Series and a Brief Review of Literature. Research & Reviews: Journal of Oncology and Hematology 2012: 1(2): 13-20
Mehta A, Jose W, Balamugesh T, Christopher DJ. Right Hilar mass with Hemoptysis - An unusual presentation of uncommon disorder. Lung India 2011; 28(4): 306-308 [PMID: 22084550]. (DOI. 10.4103/0970-2113.85698)
Jose W, Unnikrishnan A, Palaniappan M, Kumar K, Pavithran K. Simultaneous presentation of systemic lupus erythematosus (SLE) with aplastic anemia – A clinical vignette and review of literature. Journal of Clinical and Diagnostic Research 2011;5(3):637-639
Mehta AA, Jose W, Pavithran K. Hyperesoinophilic Syndrome with FIP1L1 PDGFRα Mutation: A Case Study Journal of Clinical and Diagnostic Research 2011; 5(3): 625-627
Palaniappan M, Jose W, Bindhu MR, Sudheer OV, Pavithran K. Carcinosarcoma of the Pancreas – Report of a case with a concise Review of literature. Journal of Clinical and Diagnostic Research 2011;5(3): 621-624
Jose W, Kishore K, Athira U, Pavithran K. Autoimmune Thrombocytopenic Purpura in Acute Hepatitis A – A report and review of Literature. Asia Pac J Oncol Hemat 2010; 1(2):139–141. [DOAJ: 577847]
Mehta AA, Jose W, Rajesh V, Palaniappan M, Pavithran K. Multiple Myeloma Presenting as eosinophilic Pleural Effusion. Asia–Pacific Journal of Clinical Oncology 2010;6(4):256-259. [PMID: 21114774]
Palaniappan M, Jose W, Pavithran K. Umbilical Metastatsis: A case series of four Sister Mary Joseph nodules from four different visceral malignancies. Current Oncology 2010:17(6):78-81. [PMID: 21151414]
Palaniappan M, Jose W, Pavithran K. Spontaneous hematoma of upper lip: an interesting presentation of an uncommon hematological syndrome. 2010. BLOODLINE - ONLINE JOURNAL
Gera C, Jose W, Malhotra N, Malhotra V, Dhanoa J. Radial Artery Occlusion – A Rare Presentation of Behcet’s Disease. J. Assoc Phy India 2008:56:643–44 [PMID: 19051714]

Jose W, Pavithran K. Concurrent Chemotherapy and Radiation for Carcinoma cervix. In, Rajaram S (Ed). Cervical Cancer: Contemporary Management. 1st edition. New Delhi, Jaypee Brothers Publishers, 2011; Chapter 23.
Jose W. Brain Metastases. In, Pavithran K, Uday Lal (Ed). Acute oncology for the internist (a monograph by Indian college of physicians). 1st edition. New Delhi, 2016; Chapter 23.
Jose W. Oncology – A nascent but wholesome science. In, Dipanjan Bandopadhyay (Ed) Clinical Medicine Update 2018 (a monograph by Indian Association of Clinical Medicine). 1st edition. Patiala, 2018.

Srinivasalu V K, Subramaniam N, Jose W, Philip A, Pavithran K (2018) mFLOT versus EOX in first line treatment of metastatic carcinoma of stomach. In: ESMO Asia 2018. Annals of Oncology , Volume 29, Issue suppl_9, 1 November 2018, mdy432.015, https://doi.org/10.1093/annonc/mdy432.015
Srinivasalu V K, Subramaniam N, Philip A, Jose W, Pavithran K (2018) Triple intrathecal chemotherapy for leptomeningeal carcinomatosis in solid tumours In: ESMO Asia 2018. Annals of Oncology (2018) 29 (suppl_9): ix21-ix22, https://doi.org/ 10.1093/annonc/mdy429
Srinivasalu V K, Subramaniam M, Shanmugam A, Philip A, Susan A, Prabhu R, Unni M, Sidharthan N, Jose W, Smitha NV, Pavithran K (2017) Bortezomib based versus melphalan based regimen as induction chemotherapy for primary AL amyloidosis with cardiac involvement and factors predicting early mortality In: ESMO Asia Congress. Singapore 664. Annals of Oncology, Volume 28, Issue suppl_10, 1 November 2017, mdx664, https://doi.org/10.1093/annonc/mdx664
Srinivasalu V K, Subramaniam N, Kumar N, Balasubramaniam D, Philip A, Susan A, Remesan Nair A, Prameela CG, Pushpaja KU, Thankappan K, Jose W, Iyer S, Pavithran K (2017) Do patients over 70 years with advanced head and neck squamous cell carcinoma tolerate curative intent concurrent chemo-radiation? Predictors of oncological outcomes In: ESMO Congress 2017. Annals of Oncology, Volume 28, Issue suppl_5, 1 September 2017, mdx374.033, https://doi.org/10.1093/annonc/mdx374.033
Srinivasalu V K, Subramaniam M, Shanmugam A, Philip A, Susan A, Prabhu R, Unni M, Sidharthan N, Jose W, Smitha NV, Ahamed H, Mathew N, Keechilat P (2017) Independent predictors of one year mortality in patients with primary systemic immunoglobulin light chain cardiac amyloidosis In: ESMO Congress2017. Annals of Oncology (2017) 28 (suppl_5): v355-v371. https://doi.org/10.1093/annonc/mdx373
Srinivasalu V K, George AS, Philip A, Kotne S, Bhambroo S, Vijaykumar DK, Pillai R, Beena K, Jose W, Pavithran K (2017) Effect of obesity on the toxicity profile of patients with breast cancer treated with adjuvant chemotherapy. In: ASCO 2017. J Clin Oncol 35, 2017 (suppl; abstr e12033)
Jose W (2017). Immune Modulation in Cancer. In: International Conference on Immune Response in Health and Disease. Kerala
Chelakkot PG, Ravind R, S. K, Jose WM (2016). Is triple negative breast cancer really bad? 10 year audit from a tertiary center. In: ESMO Asia 2016 Congress, Singapore. Annals Oncol (2016) 27 (suppl_9): mdw602.008.; https://doi.org/10.1093/annonc/mdw602.008
George A S, Philip A, Jose W, Durgapooorna, Bindhu MR, Pillai A, Pavithran K (2016) Outcomes of Treatment of Glioblastma Multiforme: A single institution experience fro South India (Ten year audit from a tertiary centre). In: ESMO Asia, Singapore.
Prameela CG, Rahul R, Jose W (2016) Is Triple-negative breast cancer really bad? Ten year audit from a tertiary centre. In: ESMO Asia, Singapore.
Jose W, Muniratnam V, Pavithran K, (2016) Prognostic Significance of EGFRvIII and EGFR exon 19 overexpression in Glioblastoma mutiforme in Indian patients. In: IACMCON 2016, Gwalior.
Jose W, Pavithran K, Ganesan TS (2016) Short course Lenalidomide plus Low Dose Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma – A Single Center prospective study with five years follow up. In: IACMCON 2016, Gwalior.
Philip A, Muniratnam V, Jose W, Durgapoorna, Dinesh M, Bindhu MR, Pavithran K (2016) Treatment outcome in Medulloblastoma with the POG9031 protocol: A single institution review. In: ESMO 2016, Copenhagen.
Muniratnam V, Philip A, Bindhu MR, Dinesh M, Pavithran K, Jose W (2016) Analysis of EGFRvIII and EGFR exon 19 overexpression in Glioma and its prognostic significance. In: ESMO 2016, Copenhagen.
Vijayalakshmi S, Emmanuel J, Jose WM (2015) Effectiveness of addition of olanzapine to standard antiemetic regimens in patients receiving emetogenic chemotherapy In: 66th IPC, Hyderabad.
Sidharthan N, Krishnan N, Suhas S, Shenoy P, Jose M, Jose W, Pavithran K (2014). Analysis of clinical profile and outcome of patients with hematological disorders and intracranial bleed. (Abstract H012). 5th International Hematologic Malignancies Conference. Bridging the Gap 2014, Taipei, Taiwan.
Jose M, Boyella PK, Krishnan N, Sidharthan N, Jose W, Pavithran K (2013)mStudy of prognostic significance of Neutrophilic / Lymphocytic ratio in patients with Diffuse large B cell lymphoma (DLBCL) treated with RCHOP or CHOP. In: Indian Cancer Congress, New Delhi.
Pavankumar B, Pavithran K, Jose W, Anita S, Sidharthan N (2013). Low dose Rasburicase is effective in treatment of adults with tumor lysis syndrome. Indian Cancer Congress, New Delhi.
Pillai R., Anita S, Pavan Kr. B, Jose W, Pavithran K, Durgapoorna S (2013). Hematoogiocal toxicity following treatment with Temozolomide for gliomas. Indian Cancer Congress, New Delhi.
Indu R Nair, Pavithran K, Annie J, Jose W (2013). Association of Hodgkins Lymphoma with Epstein Barr Virus – A clinicopathological study from a tertiary care centre in Kerala. Indian Cancer Congress, New Delhi.
Jose M, Boyella P K, Krishnan N, Sidharthan N, Jose W, Pavithran K (2013). Study of prognostic significance of Neutrophilic / Lymphocytic ratio in patients with Diffuse large B cell lymphoma (DLBCL) treated with RCHOP or CHOP. Indian Cancer Congress, New Delhi.
Jose W, Krishnapriya S, Nagare RP, Pavithran K, Ganesan TS (2011) Association of Tumor necrosis factor alpha - single nucleotide polymorphisms with multiple myeloma. AACR International Conference titled New Horizons in Cancer Research: Biology to Prevention to Therapy 2011, Gurgaon.
Jose W, Krishnapriya S, Nagare RP, Pavithran K, Ganesan TS (2011) Association of Tumor necrosis factor alpha - single nucleotide polymorphisms with multiple myeloma. Indian Association of Cancer Research – 30th Annual Convention 2011, Kolkata.
Jose W, Palaniappan M, Abdul Majeed, Kishore Kumar, K. Pavithran, T S Ganesan. Phase II study of Lenalidomide and short course Dexamethasone in Newly detected Multiple Myeloma. Indian Association of Cancer Research – Annual conference 2010, Kochi.
Unnikrishnan A, Sreedharan S, Jose W, Palaniappan M, Prabhu R, Unni M, Pavithran K, Bhaskaran S, Ganesan TS. The association of Jak-2 V617f mutation with polycythemia rubra vera in Asian Indians. Indian Association of Cancer Research – Annual conference 2010, Kochi.
Kumar K, Unnikrishnan A, Jose W, Ganesan TS. Role of Skeletal Scintigraphy as a standard staging investigation in patients with NSCLC. RGCON 8th International Conference, 2009, New Delhi.
Kumar K, Unnikrishnan A, Jose W, Ganesan TS. Esthesioneuroblastoma – A clinical profile. ISMPO annual conference 2009, Chennai.
Kumar K, Unnikrishnan A, Jose W, Ganesan TS. Relapsed Acute Lymphoblastic Leukemia. ISMPO Conference 2009, Chennai
Majid A, Kishore K, Jose W, Ganesan TS. Safety and efficacy of Oxaliplatin and Capecitabine as first line therapy in recurrent or metastatic colorectal cancer. International Oncology Conference 2009, Kottayam.

Organizing Member and Scientific Committee Member, ISNOCON 2015, Annual Meeting of Indian Society of Neuro-oncology, (Kochi, March 26-29, 2015)
Organizing Secretary, Amrita Breast Cancer Comprehensive Teaching Program (Kochi, January 9, 2016)
Joint Organizing Secretary, First National Cardio-Oncology Summit. (Kochi, July 29-30, 2017)

CTRI/2018/12/016813 – A Multicenter Registry Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice. CANSCRIPTTM REGISTRY OF CLINICAL UTILIZATION AND OUTCOME IN CANCER TREATMENTS (CAN-PREDICT)
SB3-G31-BC – A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin® in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting. (Sponsor: Samsung)
CBT124/CT/002 – A Randomized, Double-blind, Multicentric,Parallel-group Study Comparing Efficacy, Safety and Immunogenicity of CBT124, a Candidate Biosimilar Bevacizumab in Combination with Carboplatin and Paclitaxel with EU-sourced Avastin® in Combination with Carboplatin and Paclitaxel in First-line Treatment for Subjects with Stage IV (Unresectable Recurrent Disease or Metastatic) Non-squamous Non-Small Cell Lung Cancer (NSCLC). (Sponsor: CIPLA Biotec)
Lenalidomide and Short Course Dexamethasone In Newly Detected Multiple Myeloma – A Single Center Phase 2 Study (Sponsor: NATCO Laboratories)

RI-02-003
Reditux™ Registry to Compare Effectiveness, Safety, and Resource Utilization of Reditux™ vs. the Reference Medicinal Product to Treat Diffuse Large B-Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukaemia (CLL) in Routine Clinical Practice
LRP/LNP3794/2016/006
A Phase II/III Pivotal, Open-label, Randomized, 3 Arm Study to Assess the Efficacy of Lupin’s Molecule Monotherapy or in Combination with Docetaxel, Compared with Docetaxel Alone, in Patients with RAS Mutation Positive Locally Advanced and Metastatic Non-Small Cell Lung Cancer as Second Line Therapy
CLDK378A2301
A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer
Protocol No. 476-13
A Prospective, Comparative, Open Label, Randomized, Multicentric, Phase III study to compare the safety and efficacy of Bevacizumab of Intas Pharmaceuticals Limited against Avastin™ in Patients with Unresectable or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Protocol No. - CDP/03/07
"A randomized, multi-center, open label study to evaluate the efficacy and safety of Peg G-CSF as compared to Grafeel® in the prophylaxis of severe neutropenia in cancer patients receiving cytotoxic chemotherapy". (Sponsor: Dr. Reddy's Laboratories).
Protocol No. - MK-0683-088
"An international, Multi-center, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma". (Sponsor: Merck & Co Inc.)
Protocol No. - MORAb-003-004
"A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety Weekly Farletuzmab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum sensitive Ovarian Cancer in First Relapse" (Sponsor: Morphotek Inc.).
Protocol No: EGF 110656
"A Phase III Study of ERBB2 Positive Advanced or Metastatic Gastric or Esophageal or Gastro esophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib” (Sponsor:GlaxoSmithKline)
Protocol RI-01-002
“A Randomised, Multi-centre, Double-blind, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Two Anti-CD20 Monoclonal Antibodies in Combination with CHOP in Patients with CD20-Positive Diffuse Large B-cell Lymphoma”